With the advancement of medical technology, more and more innovative drugs have emerged, providing new solutions to the problem of weight loss. Recently, Truveta Research, a medical data and analysis company, released a remarkable study comparing the weight loss effects of two popular weight loss drugs, Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Ozempic (semaglutide). Studies have shown that Mounjaro is significantly better than Ozempic in weight loss, a finding that undoubtedly provides a new option for people seeking healthy weight loss.

Mounjaro is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism enables Mounjaro to act on two key metabolic pathways at the same time, thereby more effectively controlling blood sugar levels and promoting weight loss. Since it was approved by the US FDA for the treatment of type 2 diabetes in May 2022, Mounjaro's potential in the field of weight loss has gradually emerged.

In the Truveta study, scientists analyzed the electronic health records (EHR) of a cohort of 18,000 overweight or obese patients. These patients began treatment with Mounjaro or Ozempic between May 2022 and September 2023. The results showed that patients taking Mounjaro were three times more likely to lose 15% of their body weight than those taking Ozempic. In addition, Mounjaro also achieved faster weight loss, with an average reduction of 5.9% in body fat in three months, compared to 3.6% for patients taking Ozempic. After a year, patients taking Mounjaro had lost an average of 15.2% of their body weight, compared to an average of 7.9% for patients taking Ozempic. These data strongly demonstrate the superiority of Mounjaro in weight loss.

Ozempic is another well-known weight loss drug. As a representative of GLP-1 receptor agonists, Ozempic works by mimicking the GLP-1 hormone naturally produced by the body, reducing hunger, reducing appetite and delaying gastric emptying, thereby achieving weight control. Ozempic was first approved by the FDA in 2017 for the treatment of type 2 diabetes, and was subsequently approved in 2021 for the treatment of ordinary obese patients.

Although Ozempic has also achieved remarkable results in the field of weight loss, its weight loss effect is slightly inferior to that of Mounjaro. This may be related to Mounjaro's dual agonist mechanism, which can more comprehensively regulate metabolic processes, thereby achieving more significant weight loss effects.

In terms of safety, Mounjaro and Ozempic have similar rates of gastrointestinal events, including nausea, vomiting, diarrhea, and constipation. These adverse reactions are generally mild or moderate and are tolerable in most patients. However, for patients who use these drugs for a long time, their potential long-term side effects still need to be paid attention to.

Currently, Eli Lilly is conducting a Phase IIIb SURMOUNT-5 study to directly compare the weight loss effects of Mounjaro and Ozempic in overweight or obese patients without type 2 diabetes. In addition, Novo Nordisk has also launched its own studies to test the comparative effects of its new generation weight loss combination therapy CagriSema and Mounjaro. These studies will help further reveal the advantages and disadvantages of the two drugs and provide patients with more personalized treatment options.

Mounjaro is significantly better than Ozempic in weight loss, and this finding provides a new option for people seeking healthy weight loss. However, when choosing weight loss drugs, patients still need to consider the efficacy, safety and applicability of the drugs according to their own situation. At the same time, a healthy lifestyle, a reasonable diet and moderate exercise are still the key to successful weight loss.